Publications by authors named "E I Kulikova"

A search for violation of the charge-parity (CP) symmetry in the D^{+}→K^{-}K^{+}π^{+} decay is presented, with proton-proton collision data corresponding to an integrated luminosity of 5.4  fb^{-1}, collected at a center-of-mass energy of 13 TeV with the LHCb detector. A novel model-independent technique is used to compare the D^{+} and D^{-} phase-space distributions, with instrumental asymmetries subtracted using the D_{s}^{+}→K^{-}K^{+}π^{+} decay as a control channel.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted on B^{+} decays to explore resonant structures using data from the LHCb experiment at various energy levels, totaling an integrated luminosity of 9 fb^{-1}.
  • The researchers performed a simultaneous amplitude fit on two decay channels, determining the C parities of resonances in the D^{*±}D^{∓} mass spectra.
  • Four new charmonium or charmoniumlike states were discovered, including η_{c}(3945) and h_{c}(4000), and the presence of T_{c[over ¯]s[over ¯]0}^{*}(2870)^{0} and T_{c[over ¯]s
View Article and Find Full Text PDF

Noninvasive, rapid, and robust diagnostic techniques for clinical screening of tumors located in arbitrary areas of the human body are in demand. To address this challenge, we analyzed the feasibility of photoplethysmography-based angiography for assessing vascular structures within malignant and benign tumors. The proposed hardware and software were approved in a clinical study involving 30 patients with tumors located in the legs, torso, arms, and head.

View Article and Find Full Text PDF

A measurement of time-dependent CP violation in D^{0}→π^{+}π^{-}π^{0} decays using a pp collision data sample collected by the LHCb experiment in 2012 and from 2015 to 2018, corresponding to an integrated luminosity of 7.7  fb^{-1}, is presented. The initial flavor of each D^{0} candidate is determined from the charge of the pion produced in the D^{*}(2010)^{+}→D^{0}π^{+} decay.

View Article and Find Full Text PDF
Article Synopsis
  • Growing scientific interest in orthopoxvirus infections spurred by the 2022 mpox outbreak has led to a focus on developing new antiviral compounds.
  • This research focuses on synthesizing new 2-arylimidazoles that show effectiveness against several orthopoxviruses, including the variola virus.
  • Among the various imidazole derivatives, 1-hydroxyimidazoles stand out for their strong antiviral activity and unique structural features, with the most promising compound showing high selectivity against vaccinia and variola viruses.
View Article and Find Full Text PDF